Empirical Trials in Treatment of Gastroesophageal Reflux DiseaseFass R.
Department of Medicine, Section of Gastroenterology, Southern Arizona V.A. Halth Care System and University of Arizona Health Sciences Center, Tucson, Ariz., USA
The assortment of diagnostic tests that are currently available for detecting gastroesophageal reflux disease (GERD) are invasive, costly and not readily available to community-based physicians. In contrast, a short course of high-dose proton pump inhibitor (PPI) as an empirical trial is an attractive alternative. This simple diagnostic test has been demonstrated to be accurate and cost-effective in patients with symptoms suggestive of GERD and those with noncardiac chest pain. Early studies in patients with extraesophageal manifestations of GERD have yielded promising results. Cost assessment of the PPI empirical trial revealed significant cost savings, mainly due to a marked decrease in utilization of invasive diagnostic tests. Thus the PPI empirical trial should be considered as the initial diagnostic step in patients with the disease spectrum of GERD.
Ronnie Fass, MD
Southern Arizona V.A. Health Care System, 3601 S 6th Avenue
Section of Gastroenterology 111G1
Tucson, AZ 85723 (USA)
Tel. +1 520 792 1450/ext. 5139, Fax +1 520 529 4737, E-Mail firstname.lastname@example.org
Number of Print Pages : 7
Number of Figures : 0, Number of Tables : 3, Number of References : 49
Digestive Diseases (State-of-the-Art Clinical Reviews)
Formerly ‘Survey of Digestive Diseases’; Founded in 1983 by T.S.N. Chen and R.K. Zetterman
Vol. 18, No. 1, Year 2000 (Cover Date: 2000)
Journal Editor: S.R. Achem, Jacksonville, Fla.
ISSN: 0257–2753 (print), 1421–9875 (Online)
For additional information: http://www.karger.com/journals/ddi